Table 1.
Demographic data of the safety set in the COMPONENT trial
| Vidofludimus (N = 122) | Placebo (N = 119) | Total (N = 241) | |
|---|---|---|---|
| Sex | |||
| Female | 101 (82.8%) | 99 (83.2%) | 200 (83.0%) |
| Male | 21 (17.2%) | 20 (16.8%) | 41 (17.0%) |
| Race | |||
| Caucasian | 122 (100.0%) | 119 (100.0%) | 241 (100.0%) |
| Age (years) | |||
| Mean (SD) | 56.4 (10.6) | 56.9 (10.1) | 56.6 (10.3) |
| Median | 57 | 58 | 57 |
| Minimum | 21 | 29 | 21 |
| Maximum | 81 | 77 | 81 |
| Weight (kg) | |||
| Mean (SD) | 71.5 (14.9) | 73.6 (14.8) | 72.5 (14.9) |
| Median | 70 | 73 | 71 |
| Minimum | 49 | 44 | 44 |
| Maximum | 126 | 117 | 126 |
| Height (cm) | |||
| Mean (SD) | 164.0 (8.2) | 164.0 (6.7) | 164.0 (7.5) |
| Median | 164 | 164 | 164 |
| Minimum | 140 | 146 | 140 |
| Maximum | 192 | 185 | 192 |
| BMI (kg/m2) | |||
| Mean (SD) | 26.6 (5.0) | 27.4 (5.5) | 27.0 (5.3) |
| Median | 26 | 27 | 26 |
| Minimum | 18 | 18 | 18 |
| Maximum | 40 | 46 | 46 |
BMI body mass index, N number of patients, SD standard deviation